Paper Overview
Field: Computer Vision Authors: Arne Schmidt, Justin Nieder, Cornelius Boehm, Julika Ribbat-Idel, Marius Teodorescu Published: 2026-11-09 arXiv: 2611.12855
Abstract (English)
Mature tertiary lymphoid structures (TLS) containing germinal centers and mature lymph-node follicles (secondary lymphoid structures, SLS) sustain plasma cell responses that shape prognosis and immunotherapy benefit in lung cancer. How this regional axis differs between neoadjuvant-treated and therapy-naive tumors was previously unclear.
The authors analyzed H&E whole-slide images from resected tumors and paired proximal/distal lymph nodes of 20 matched neoadjuvant-treated (neoLUSC) and 20 therapy-naive (naivLUSC) lung squamous cell carcinoma patients. The Aignostics Atlas H&E tissue analysis model quantified cell densities and co-localization per tissue compartment; a dedicated deep learning model validated against pathologist annotations detected TLS/SLS and assessed maturity. Prognostic value was tested in an independent cohort (n=458, including 46 treated cases).
Key Findings
- Stromal plasma cell density was 72% lower in neoLUSC tumors (p=0.004); stromal lymphocyte density was 48% lower (p=0.015). Macrophages and granulocytes showed no significant difference.
- Total and immature TLS counts were unchanged, but mature TLS in tumors (p=0.034) and mature SLS in tumor-distant lymph nodes (p=0.003) were lower in neoLUSC.
- Peri-TLS plasma cell density correlated with tumor lymphocyte density in naivLUSC (rho=0.54, p=0.017), but this association was absent in neoLUSC (rho=0.07).
- In the validation cohort, stromal plasma cell density (HR 0.69, p=0.011) and lymphocyte-plasma cell co-localization (HR 0.66, p=0.004) were associated with longer survival, while neoadjuvant treatment status was associated with shorter survival (HR 1.50, p=0.026).
Conclusion
Neoadjuvant therapy is associated with a reduction in mature lymphoid structures and weakened humoral compartment-tumor coupling, rather than a global dampening of immune readouts. The stromal plasma cell / co-localization axis is a candidate prognostic biomarker.
--- *Automatically collected on 2026-11-11*